10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 801–900 of 1,169
Metformin as a geroprotector: experimental and clinical evidence
Piskovatska, V., Stefanyshyn, N., Storey, K. B., Vaiserman, A. M., & Lushchak, O. V. (2018) · Biogerontology · doi:10.1007/s10522-018-9773-5 · Cited by 114
“These include various aspects of metabolic syndrome including impaired glucose tolerance (Hostalek et al. 2015), obesity (Berstein 2012) and hypertension (Zhou et al. 2017), and also risk factors for CVD development such as atherosclerosis (Jenkins et al. 2018) and endothelial dysfunction (Nesti…”
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 110
Self-citationHsu, C., Chang, H., Huang, M., Hwang, S., Yang, Y., Lee, Y. S., Shin, S. J., & Tai, T. Y. (2012) · Diabetologia · doi:10.1007/s00125-012-2700-4 · Cited by 121
“However, the follow-up study of the UK Prospective Diabetes Study demonstrated the important role of early strict glycaemic control in preventing vascular complications [16], implying that an indicator that needs to track HbA1c measurements for more than 5 years to correlate its clinical implications may be late for a…”
BackgroundAlonso-Morán, E., Orueta, J. F., Esteban, J. I. F., Axpe, J. M. A., González, M. L. M., Polanco, N. T., Loiola, P. E., Gaztambide, S., & Nuño-Solinis, R. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-1059 · Cited by 110
The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes
Hooper, P. L., Balogh, G. E., Rivas, E., Kavanagh, K., & Vígh, L. (2014) · Cell Stress and Chaperones · doi:10.1007/s12192-014-0493-8 · Cited by 118
“…metformin, is a xenohormetic plant compound that increases membrane fluidity , raises Hsps, restores metabolic homeostasis, reduces cancer risk, and reduces diabetic mortality (Hooper et al. 2010; Tsuei and Martinus 2012; Nunn et al. 2010; Muller et al. 1997; Wiernsperger 1999; Holman et al. 2008).”
BackgroundShea, M. K., Houston, D. K., Nicklas, B. J., Messier, S. P., Davis, C. C., Miller, M. E., Harris, T. B., Kitzman, D. W., Kennedy, K., & Kritchevsky, S. B. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp217 · Cited by 110
Aschner, P. J., Chan, J. C. N., Owens, D. R., Picard, S., Wang, E., Dain, M., Pilorget, V., Echtay, A. S., & Fonseca, V. A. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60439-5 · Cited by 115
Systematic review of palm oil consumption and the risk of cardiovascular disease
Ismail, S. R., Maarof, S. K., Ali, S. S., & Ali, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193533 · Cited by 118
Kim, K. B., Lee, W.-C., Cho, C.-H., Park, D., Cho, S. J., & Shim, Y. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.10.081 · Cited by 110
Bromocriptine: old drug, new formulation and new indication
Holt, R. I. G., Barnett, A. H., & Bailey, C. J. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01304.x · Cited by 110
“As evidence accumulates showing the importance of early glycaemic control, earlier and more effective pharmacological intervention is indicated, highlighting the need for additional blood glucose lowering agents, acting through different mechanisms [2].”
BackgroundHortensius, J., Kars, M. C., Wierenga, W. S., Kleefstra, N., Bilo, H. J., & van der Bijl, J. J. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-167 · Cited by 103
“The Diabetes Control and Complication Trial [1] and the United Kingdom Prospective Diabetes Study [2] demonstrated that strict glycemic control significantly decreases the risk of long-term diabetes complications.”
BackgroundMean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study
Elder, D. H. J., Singh, J. S. S., Levin, D., Donnelly, L. A., Choy, A.-M., George, J., Struthers, A. D., Doney, A. S. F., & Lang, C. C. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.455 · Cited by 109
Jarvis, J., Skinner, T. C., Carey, M. E., & Davies, M. J. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01098.x · Cited by 102
Giaccari, A., Sorice, G. P., & Muscogiuri, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.018 · Cited by 121
“[110] UK Prospective Diabetes Study (UKPDS) Group.”
InfluentialNew forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
Hemmingsen, B., Christensen, L. L., Wetterslev, J., Vaag, A., Gluud, C., Lund, S. S., & Almdal, T. (2012) · BMJ · doi:10.1136/bmj.e1771 · Cited by 108
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 127
“Despite the small number of patients enrolled, the protective effects of metformin were still observed in the 10-year posttrial monitoring of patients who survived to the end of the UKPDS trial.(18) Although HbA1c levels were no longer different between intensive and conventional arms, metformin-related risk reduction…”
BackgroundResultDirect cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Kaplan, A., Abidi, E., EL‐Yazbi, A. F., Eid, A. H., Booz, G. W., & Zouein, F. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9665-9 · Cited by 114
Dambha-Miller, H., Feldman, A. L., Kinmonth, A. L., & Griffin, S. J. (2019) · The Annals of Family Medicine · doi:10.1370/afm.2421 · Cited by 96
Colom, C., Rull, A., Sánchez‐Quesada, J. L., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081798 · Cited by 118
“In addition, DCCT and UKPDS studies that enrolled relatively young T1DM adults and newly diagnosed T2DM patients, respectively, found reductions in CVD after prolonged follow-up, despite the fact that the initial difference in glycemic control was not maintained during follow-up [131,132].”
Hormones and Aging: An Endocrine Society Scientific Statement
Cappola, A. R., Auchus, R. J., Fuleihan, G. E., Handelsman, D. J., Kalyani, R. R., McClung, M. R., Stuenkel, C. A., Thorner, M. O., & Verbalis, J. G. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad225 · Cited by 122
Diabetic kidney disease: act now or pay later
Atkins, R. C., & Zimmet, P. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.10 · Cited by 111
“For example, the UKPDS [19,20], STENO-2”
Comprehensive approach to diabetic nephropathy
Satirapoj, B., & Adler, S. G. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.08.001 · Cited by 123
“Moreover, after termination of the UKPDS study, patients with type 2 diabetes randomized to the lower HbA1c target continued to experience risk reduction for myocardial infarction and death from any cause up to 10 years after the original randomized assignment, in some cases despite higher subsequent HbA1c after the s…”
MethodClinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes
Owens, D. R. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0081 · Cited by 106
“Earlier initiation of such a treatment option, before the loss of further function, may be more effective in providing long-term efficacy against the complications of T2DM, as suggested by the long-term observations in the follow-up study of the United Kingdom Prospective Diabetes Study (UKPDS).(10,24)”
InfluentialPharmacological Treatment and Current Management of Peripheral Artery Disease
Bonaca, M. P., & Creager, M. A. (2015) · Circulation Research · doi:10.1161/circresaha.114.303505 · Cited by 112
“007).(55) The benefit was seen in spite of no attempt to maintain previously assigned therapies in the extension and loss of glycemic difference.”
BackgroundInfluentialMetformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells
Yang, X., Xu, Z., Zhang, C., Cai, Z., & Zhang, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.019 · Cited by 121
Effects of glycaemic management on diabetic kidney disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i5.172 · Cited by 118
Bacha, F., Gungor, N., Lee, S., & Arslanian, S. A. (2013) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2012.00915.x · Cited by 106
“In the United Kingdom Prospective Diabetes Study (UKPDS), the estimated rate of decline of β-cell function, using the Homeostasis Model Assessment (HOMA %B) index, was about 7% per year (3, 4).”
BackgroundResultRitsinger, V., Malmberg, K., Mårtensson, A., Rydén, L., Wedel, H., & Norhammar, A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70088-9 · Cited by 118
Ceriello, A., Testa, R., & Genovese, S. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.006 · Cited by 119
Lifestyle Changes After a Diagnosis of Type 2 Diabetes
Chong, S., Ding, D., Byun, R., Comino, E. J., Bauman, A. E., & Jalaludin, B. B. (2017) · Diabetes Spectrum · doi:10.2337/ds15-0044 · Cited by 118
Deng, Z., Bi, S., Jiang, M., & Zeng, S. (2021) · ACS Nano · doi:10.1021/acsnano.0c09799 · Cited by 107
Khalid, J. M., Raluy-Callado, M., Curtis, B., Boye, K. S., Maguire, A., & Reaney, M. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12265 · Cited by 120
Association of Glycemic Control with Risk of Erectile Dysfunction in Men with Type 2 Diabetes
Lu, C.-C., Jiann, B.-P., Sun, C.-C., Lam, H.-C., Chu, C.-H., & Lee, J.-K. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01219.x · Cited by 104
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
The Roles of Glycated Albumin as Intermediate Glycation Index and Pathogenic Protein
Kim, K. J., & Lee, B. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.2.98 · Cited by 111
Intensive Multifactorial Intervention for Stable Coronary Artery Disease
Maron, D. J., Boden, W. E., O’Rourke, R. A., Hartigan, P. M., Calfas, K. J., Mancini, G. B. J., Spertus, J. A., Dada, M. R., Kostuk, W. J., Knudtson, M. L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.062 · Cited by 117
Ogawa, S., Nakayama, K., Nakayama, M., Mori, T., Matsushima, M., Okamura, M., Senda, M., Nako, K., Miyata, T., & Ito, S. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.156786 · Cited by 106
Laiteerapong, N., Karter, A. J., Moffet, H. H., Cooper, J. M., Gibbons, R. D., Liu, J. Y., Gao, Y., & Huang, E. S. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.023 · Cited by 101
“The differential findings for microvascular and macrovascular events are consistent with the temporal findings from the UKPDS (UK Prospective Diabetes Study (UKPDS) Group, 1998a, 1998b; Holman et al., 2008).”
InfluentialKhunti, K., Kosiborod, M., & Ray, K. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13243 · Cited by 104
“The United Kingdom Prospective Diabetes Study (UKPDS) in newly diagnosed individuals with T2DM also observed this phenomenon and demonstrated that tight glycaemic control for a period of time was associated with microvascular and microvascular benefits that persisted during the 10-year follow-up, despite the fact that…”
BackgroundMetas no tratamento do diabetes
de Almeida-Pititto, B., Rodrigues, M. L. D., de Moura, F. F., Lamounier, R. N., Vencio, S. A. C., Calliari, L. E., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-3 · Cited by 104
The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
Napoli, N., Strollo, R., Paladini, A., Briganti, S., Pozzilli, P., & Epstein, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/690783 · Cited by 110
Zafar, A., Stone, M. A., Davies, M. J., & Khunti, K. (2015) · Diabetic Medicine · doi:10.1111/dme.12592 · Cited by 103
Complications du diabète de type 2
Schlienger, J.-L. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.02.313 · Cited by 148
A peer support intervention in improving glycemic control in patients with type 2 diabetes
Peimani, M., Monjazebi, F., Ghodssi-Ghassemabadi, R., & Nasli‐Esfahani, E. (2017) · Patient Education and Counseling · doi:10.1016/j.pec.2017.10.007 · Cited by 103
Pathophysiological Fundamentals of Diabetic Cardiomyopathy
Hu, X., Bai, T., Xu, Z., Liu, Q., Zheng, Y., & Cai, L. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160021 · Cited by 119
Schneider, A. L. C., Kalyani, R. R., Golden, S., Stearns, S. C., Wruck, L., Yeh, H. C., Coresh, J., & Selvin, E. (2016) · Diabetes Care · doi:10.2337/dc15-1335 · Cited by 102
A Review on the Relationship between SGLT2 Inhibitors and Cancer
Lin, H.-W., & Tseng, C.-H. (2014) · International Journal of Endocrinology · doi:10.1155/2014/719578 · Cited by 99
“More intensive glycemic control in newly diagnosed type 2 diabetic patients may reduce long-term cardiovascular disease rates [5].”
BackgroundSmith, R. J., Nathan, D. M., Arslanian, S. A., Groop, L., Rizza, R. A., & Rotter, J. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1966 · Cited by 100
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.881003 · Cited by 103
“9) and a mean (SD) of 16 (6) months; patients allocated to glipizide were adherent (took 80% and 120% of their study medications) at 90.”
Thiem, K., Keating, S. T., Netea, M. G., Riksen, N. P., Tack, C. J., van Diepen, J. A., & Stienstra, R. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.1901348 · Cited by 110
“termed “hyperglycemic memory” (6) and exemplifies the persistent and harmful effects of hyperglycemia.”
BackgroundGembillo, G., Ingrasciotta, Y., Crisafulli, S., Luxi, N., Siligato, R., Santoro, D., & Trifirò, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094824 · Cited by 113
The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes
Lind, M., Olsson, M., Rosengren, A. H., Svensson, A., Bounias, I., & Guðbjörnsdóttir, S. (2012) · Diabetologia · doi:10.1007/s00125-012-2681-3 · Cited by 114
“Myocardial infarction, the most common manifestation of CVD in type 2 diabetes, has been shown to be reduced by intensive glycaemic control, improved blood lipids and reduction in BP [4–6].”
BackgroundShirakawa, S., Matsumoto, I., Toyama, H., Shinzeki, M., Ajiki, T., Fukumoto, T., & Ku, Y. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2039-7 · Cited by 103
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
Sundelin, E., Gormsen, L., Jensen, J., Vendelbo, M., Jakobsen, S., Munk, O., Christensen, M., Brøsen, K., Frøkiær, J., & Jessen, N. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.701 · Cited by 100
Perceptions of insulin use in type 2 diabetes in primary care: a thematic synthesis
Ellis, K., Mulnier, H., & Forbes, A. (2018) · BMC Family Practice · doi:10.1186/s12875-018-0753-2 · Cited by 93
Gomes, M. B., Rathmann, W., Charbonnel, B. H., Khunti, K., Kosiborod, M., Nicolucci, A., Pocock, S., Shestakova, M. V., Shimomura, I., Tang, F., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.024 · Cited by 101
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012356 · Cited by 99
Vesa, C. M., Popa, L., Popa, A. R., Rus, M., Zaha, A. A., Bungau, S., Tit, D. M., Corb Aron, R. A., & Zaha, D. C. (2020) · Diagnostics · doi:10.3390/diagnostics10050314 · Cited by 96
“Another study, carried out for recently diagnosed T2DM patients who received more intensive treatment, showed 15% MI risk reduction in patients receiving sulphonylurea or insulin and a 33% reduction in those receiving metformin [31].”
BackgroundResultInfluentialType 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk
Gerich (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8216 · Cited by 100
Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney
Marinis, Y. Z. D., Cai, M., Bompada, P., Atac, D., Kotova, O., Johansson, M., Garcia‐Vaz, E., Gomez, M. F., Laakso, M., & Groop, L. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.018 · Cited by 102
Nyane, N. A., Tlaila, T. B., Malefane, T. G., Ndwandwe, D. E., & Owira, P. M. O. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.042 · Cited by 101
Cardiac Abnormalities in Youth with Obesity and Type 2 Diabetes
Bacha, F. F., & Gidding, S. S. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0750-6 · Cited by 110
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
Sasso, F. C., Rinaldi, L., Lascar, N., Marrone, A., Pafundi, P. C., Adinolfi, L. E., & Marfella, R. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3106056 · Cited by 98
“On the other hand, the UKPDS [6] did not demonstrate a significant reduction of macrovascular events during the intensive treatment, whilst showing that the benefits of an intensive strategy to control blood glucose levels appeared 10 years after the end of treatments [7].”
Lunder, M., Janić, M., Japelj, M., Juretič, A., Janež, A., & Šabović, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0797-6 · Cited by 105
Liu, L., Xia, R., Song, X., Zhang, B., He, W., Zhou, X., Li, S., & Yuan, G. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13371 · Cited by 100
Slinin, Y., Ishani, A., Rector, T., Fitzgerald, P., MacDonald, R., Tacklind, J., Rutks, I., & Wilt, T. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.017 · Cited by 99
Powell, R. E., Zaccardi, F., Beebe, C., Chen, X. M., Crawford, A., Cuddeback, J., Gabbay, R. A., Kissela, L., Litchman, M. L., Mehta, R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14455 · Cited by 99
“These benefits can persist even if the targets achieved early are not sustained.(4) Despite the availability of effective treatment options and wellestablished management guidelines, corresponding improvement in reaching glycaemic targets has lagged.”
BackgroundHelmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“…glycaemic control since the achieved HbA1c reduction was relatively small (mostly <0.7%; see Table 1) and optimisation of hyperglycaemia usually takes a time to benefit the primary CV outcome as demonstrated in UKPDS trial (a 15% reduction in MI emerged over 10 years) (Holman et al., 2008).”
MethodInfluentialBoye, K. S., Thieu, V. T., Lage, M. J., Miller, H., & Paczkowski, R. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02106-4 · Cited by 99
“Specifically, 10 years of additional observational follow-up after UKPDS revealed statistically significantly lower rates of both myocardial infarction and all-cause death among those who were initially randomized to the intensive treatment cohort [31], while Fig.”
BackgroundMoody, A., Cowley, G., Ng Fat, L., & Mindell, J. S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010155 · Cited by 95
Sharma, A., Rizky, L., Stefanovic, N., Tate, M., Ritchie, R. H., Ward, K. W., & de Haan, J. B. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0513-y · Cited by 97
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases
Yamagishi, M., Tamaki, N., Akasaka, T., Ikeda, T., Ueshima, K., Uemura, S., Otsuji, Y., Kihara, Y., Kimura, K., Kimura, T., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-19-1131 · Cited by 107
Recent advances on biomedical applications of pectin-containing biomaterials
Eivazzadeh‐Keihan, R., Noruzi, E. B., Aliabadi, H. A. M., Sheikhaleslami, S., Akbarzadeh, A. R., Hashemi, S. M., Gorab, M. G., Maleki, A. R., Cohan, R. A., Mahdavi, M. R., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.016 · Cited by 100
Diabetes in the Western Pacific Region—Past, Present and Future
Chan, J. C. N., Cho, N. H., Tajima, N., & Shaw, J. E. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.012 · Cited by 108
Terry, T., Raravikar, K., Chokrungvaranon, N., & Reaven, P. D. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0238-6 · Cited by 103
Venkatesh, B., Pilcher, D., Prins, J., Bellomo, R., Morgan, T. J., & Bailey, M. (2015) · Critical Care · doi:10.1186/s13054-015-1171-7 · Cited by 96
“In the last two decades, diabetes management has undergone paradigm shifts with increased public health education, improved insulin delivery methods, better targeting of oral hypoglycaemic agents and more intensive monitoring [19, 20].”
BackgroundEffects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Martino, A. D., Albanese, G., Marfella, R., Sardu, C., et al. (2021) · Biomolecules · doi:10.3390/biom11121834 · Cited by 102
“Above all, indication for use was strengthened based on its assumed favorable and long-lasting benefits on CV morbidity and mortality, best demonstrated by the 10-year follow-up of the landmark UKPDS trial [4,5].”
BackgroundThe Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy—A Review of the Literature
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Nutrients · doi:10.3390/nu14061252 · Cited by 112
Siddiqi, F. S., Majumder, S., Thai, K., Abdalla, M., Hu, P., Advani, S. L., White, K., Bowskill, B. B., Guarna, G., dos Santos, C. C., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090898 · Cited by 102
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Whalen, K., Miller, S. A., & Onge, E. S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.004 · Cited by 103
“Substantial evidence indicates that controlling blood glucose prevents the risk or reduces progression of microvascular complications.(4,5) Furthermore, controlling other risk factors such as hypertension and dyslipidemia reduces the risk of both nephropathy and retinopathy and is paramount to decreasing the occurrenc…”
BackgroundPantalone, K. M., Wells, B. J., Chagin, K. M., Ejzykowicz, F., Yu, C., Milinovich, A., Bauman, J. M., Kattan, M. W., Rajpathak, S., & Zimmerman, R. S. (2016) · Diabetes Care · doi:10.2337/dc16-0227 · Cited by 96
“Missing 759 (15) 156 (13) 102 (15) 67 (16)”
BackgroundCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92
Gourgari, E., Wilhelm, E. E., Hassanzadeh, H., Aroda, V. R., & Shoulson, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.005 · Cited by 95
Conlin, P. R., Colburn, J., Aron, D., Pries, R. M., Tschanz, M. P., & Pogach, L. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1362 · Cited by 97
Diabetes mellitus: diagnosis and screening.
Patel, P., & Macerollo, A. A. (2010) · PubMed · Cited by 127
Metabolic memory: Mechanisms and implications for diabetic retinopathy
Zhang, L., Chen, B., & Tang, L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.006 · Cited by 103
Pruijm, M., Hofmann, L., Piskunowicz, M., Muller, M.-E., Zweiacker, C., Bassi, I., Vogt, B., Stuber, M., & Burnier, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095895 · Cited by 96
“The herein described association offers an alternative explanation in humans for to the relationship between badly controlled diabetes mellitus and adverse renal outcome [35].”
BackgroundBeulens, J. W. J., Hart, H. E., Kuijs, R., Kooijman-Buiting, A. M. J., & Rutten, G. E. H. M. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0597-8 · Cited by 109
“Metformin is not associated with hypoglycemias nor weight gain and reduces the risk of complications and mortality [3, 4].”
Global DNA methylation as a possible biomarker for diabetic retinopathy
Maghbooli, Z., Hossein‐nezhad, A., Larijani, B., Amini, M., & Keshtkar, A. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2584 · Cited by 97
Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
“In the UKPDS, insulin had no significant effect on any macrovascular outcome [38] and its contribution to the delayed benefit of intensive therapy at follow-up was not investigated [33].”
BackgroundInfluentialValue of Self-Monitoring Blood Glucose Pattern Analysis in Improving Diabetes Outcomes
Parkin, C. G., & Davidson, J. A. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300314 · Cited by 96
Jonas, D. E., Crotty, K., Yun, J. D. Y., Middleton, J. C., Feltner, C., Taylor-Phillips, S., Barclay, C., Dotson, A., Baker, C., Balio, C. P., et al. (2021) · JAMA · doi:10.1001/jama.2021.10403 · Cited by 96
Home, P. D., Fritsche, A., Schinzel, S., & Massi‐Benedetti, M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01232.x · Cited by 96
Fonseca, V. A., DeVries, J. H., Henry, R. R., Donsmark, M., Thomsen, H. F., & Plutzky, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.009 · Cited by 98
Pharmacogenetics of Anti-Diabetes Drugs
DiStefano, J. K., & Watanabe, R. M. (2010) · Pharmaceuticals · doi:10.3390/ph3082610 · Cited by 107
“Maintenance of near-normal glycemic levels has been shown to lessen the risk for development and progression of disease complications [28].”
BackgroundDiffering Effects of Metformin on Glycemic Control by Race-Ethnicity
Williams, L. K., Padhukasahasram, B., Ahmedani, B. K., Peterson, E. L., Wells, K. E., González Burchard, E., & Lanfear, D. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1539 · Cited by 95
Siersbæk, M. S., Varticovski, L., Yang, S., Baek, S., Nielsen, R., Mandrup, S., Hager, G. L., Chung, J. H., & Grøntved, L. (2017) · Scientific Reports · doi:10.1038/srep40220 · Cited by 106
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.